Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026

Revelation Biosciences (NASDAQ:REVB) reported financial results for the three and six months ended June 30, 2026. Cash and cash equivalents rose to $11.5M from $10.7M at Dec. 31, 2025, and it expects funding through Q1 2027. Net loss was $3.3M ($0.87/share) for Q2 and $6.3M ($3.41/share) for six months. The company also advanced Gemini AKI Phase 2/3 start-up and formed an AKI advisory board.

Original reporting
Published Aug 6, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$REVB
Neutral
medium confidence
Mentioned
$REVB
Relevance
6/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$REVBNeutralMed
01

Why it matters

The key tradable elements are updated financials (cash, burn, net loss) and management’s runway statement, plus continued Phase 2/3 start-up progress for GEM-AKI.

02

Market read

This is a company-specific financial update with a stated cash runway through Q1 2027 and ongoing clinical start-up activity, but no new clinical outcome or regulatory decision.

03

What to watch

The article highlights AKI advisory board formation and Gemini market assessment TAM, but does not provide enrollment timing confirmation or any new Phase 2/3 efficacy data, which may be what the market ultimately prices.

Relevance 6/10Novelty 6/10Timing: post-close today, for positioning ahead of next clinical and financing expectations

Background

Revelation Biosciences is a clinical-stage company developing Gemini, a TLR4 agonist formulation, across acute kidney injury and other inflammatory indications.

Company-level read

Ticker impact

$REVBNeutralMedium confidence
Context

Revelation reported cash of $11.5M at June 30, 2026 and said it funds operations through Q1 2027, alongside higher net losses.

Expected impact

Likely modest, sentiment-driven reaction unless investors view the cash runway and burn as improving versus expectations.

Evidence & confidence

The release provides balance-sheet runway guidance (through Q1 2027) and updated operating/burn figures, but no new clinical efficacy or regulatory milestone.

Market effects

Adds another data point on funding runway and burn dynamics for clinical-stage biotech, which can influence risk appetite for similar small-cap names.

Limited, primarily impacts US small-cap biotech sentiment.

Low, as the disclosure is company-specific and not tied to a global macro or regulatory event.

Counterpoint

Investors may treat the higher cash balance and stated funding runway through Q1 2027 as reducing immediate dilution risk, offsetting the larger net loss.

Key entities

  • Revelation Biosciences, Inc.

    Clinical-stage life sciences company developing Gemini for inflammatory diseases, including acute kidney injury.

  • Gemini (PHAD, TLR4 agonist)

    Proprietary formulation being evaluated in GEM-AKI and other indications.

  • Acute Kidney Injury Advisory Board

    Advisory board formation and expansion tied to the upcoming Phase 2/3 AKI trial.

Related articles

$REVBLow

Revelation Biosciences, Inc. Announces Financial Results

REVELATION BIOSCIENCES, INC. (REVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026 SAN DIEGO – November 5, 2026 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developi

$REVBMedAI 8/10

Revelation Aiming for Paradigm Shift in Kidney Disease Care

Revelation Biosciences (REVB) is developing Gemini, a drug candidate for acute and chronic kidney disease, post-surgical infections, and severe burns. The company plans to launch a Phase 2/3 study for acute kidney injury later this year, with completion expected in about two years. CEO James Rolke highlights Gemini's potential to reduce inflammation and prevent scar tissue, citing positive pre-clinical and early clinical results. Revelation aims to submit Gemini for FDA approval if the study mee

$REVBMed

Revelation Biosciences, Inc. Announces Financial Results

REVELATION BIOSCIENCES, INC. (REVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results For the Three and Six Months Ended June 30, 2026 SAN DIEGO – August 6, 2026 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innov

$XPMedAI 8/10

XP Q3 2026 slides: asset growth strong, but margin pressure evident

XP Inc. reported Q3 2026 earnings with total client assets up 15% YoY to R$2.2T, but net margins contracted to 26.9%. Revenue grew 8% YoY to R$5.3B, while SG&A expenses rose 12% YoY. Shares fell 4.26% post-earnings. The company is diversifying revenue, with non-investment revenues now 20% of retail revenue. Management expects 10% annual top-line growth in 2027.

$LUVUMed

Luvu Brands, Inc.: Luvu Brands Reports First Quarter Fiscal 2027 Results: 10% Net Sales Growth, Wholesale Sales Up 12%

Luvu Brands (LUVU) reported Q1 FY2027 results with net sales up 10% to $6.78M, wholesale sales up 12.3% to $4.72M, and direct-to-consumer sales up 5.3% to $2.06M. Gross profit fell 10.1% to $1.78M due to higher freight and labor costs, resulting in an operating loss of $332K and a net loss of $365K. Cash from operations increased to $120K, and cash reserves were $1.02M.